Table 1.
Baseline characteristics of included patients with metastatic breast cancer.
Table 2.
Types of detected lesions and lesion-based sensitivity by each modality.
Fig 1.
A 54-year-old woman with true-positive bone metastases.
A) Whole-body bone scintigraphy shows only one area with increased uptake of 99mTc-DPD (arrow). B) FDG-PET 1h and 3h images show multiple osseous metastases in the spine and the pelvis. C) Axial FDG-PET/CT images demonstrating FDG-avid lesions in the spine, sacrum, and iliac bones. D) Axial CT images at the same level as C show osteolytic changes.
Fig 2.
A 71-year-old woman with true-positive bone metastases.
A) Whole-body bone scintigraphy shows few areas with increased uptake of 99mTc-DPD osteolytic lesions. B) FDG-PET images show multiple osseous metastases in the skeleton and metastases in other organs on 1h and 3h images. C) Axial 1h and 3h FDG-PET/CT images showing FDG-avid lesions in the spine, sacrum, and iliac bones. D) Axial CT images at the same level as C show osteolytic changes.
Fig 3.
Comparison of early and delayed corrected standardized uptake value for partial volume within different lesion types (FDG-PET/CT: Fluorodeoxyglucose positron emission tomography with integrated computed-tomography; Corrected-SUVmean: Corrected standardized uptake value for partial volume).
Table 3.
FDG uptake and metabolically active volume in types of bone metastasis*.